Biocartis

We're #hiring a new Senior Financial Analyst/Finance Manager in Chicago, Illinois. Apply today or share this post with your network.

Sometimes, the easiest solution can have the most life-changing impact ☃️ Molecular biomarker results in ONLY 3 HOURS! 💡THINK IDYLLA™ ⭐ Biocartis wishes you a wonderful holiday season & a joyful 2025! ⭐ And don’t forget, the easiest solution is often right under your nose… 🥕 #Biocartis #Idylla #HappyHolidays #BiomarkerTesting #MolecularDiganostics

📣 Our partner, C Sixty Pan Asia LTD (Hong Kong) is in the news with Idylla™ ThyroidPrint ® Assay (RUO*) 👏 📚 Read the article: https://lnkd.in/g2N4Fp9d 📽️ Watch the interview: https://lnkd.in/e9JQNZ6q 🔎 Get more info on Idylla™ ThyroidPrint® Assay (RUO*): https://lnkd.in/etU7JVTg *For Research Use Only (RUO), not for use in diagnostic procedures. Developed by Geneprodx and distributed by Biocartis

📣 Publication News from Germany   The Idylla™ BRAF Mutation Test (CE-IVD*) was shown to be a “reliable and rapid alternative to NGS” for detecting BRAF V600 mutations in melanoma (Lenders et al., 2024).    Here’s why Idylla™ stands out: ✅ Same-day results for faster decision-making ✅ Shorter turnaround time: Just 0.2 days vs. NGS at 12.2 days ✅ 100% concordance with NGS ✅ Less tumor material required compared to NGS ✅ Accelerates treatment for high-burden cases   📚 Read the full publication: https://lnkd.in/eGUTbRwu 🕵️♀️ Discover the Idylla™ BRAF Mutation Test (CE-IVD*): https://lnkd.in/eZa2mbbZ *Idylla™ BRAF Mutation Test is CE-marked in Europe in compliance with the EU IVD directive 98/79/EC, but is for Research Use Only (RUO), not for use in diagnostic procedures, in the US.  #Melanoma #BRAFV600 #BRAF #Biocartis #Idylla 

Why use the Idylla™ ThyroidPrint® Assay (RUO*)? 🤔 💙 For risk stratification of indeterminate thyroid nodules ✅ Fully automated ✅ Ultra-rapid: 160 minutes turnaround time ✅ Limited sample input ✅ On-demand ✅ Excellent preliminary results vs ThyroidPrint® Laboratory Developed Test Convinced? Check out more information here 👀 https://lnkd.in/etU7JVTg Developed by Geneprodx, distributed by Biocartis *For Research Use Only (RUO), not for use in diagnostic procedures. #Idylla #ThyroidPrint #ThyroidNodules #ThyroidCancer #Thyroid ThyroidPrint ®

Test for EGFR, ALK, ROS1, RET and METex14 in ONLY 3 HOURS and immediately start the right targeted therapy for >90% of your patients with first-line actionable biomarkers*. IDYLLA™ FIRST. Guiding First-Line Therapy Decisions in NSCLC ⏱️ Learn more 👉🏻 https://lnkd.in/enNpBhir #Biocartis #Idylla #EGFR #GeneFusion #ALK #ROS1 #RET #METex14 #LungCancer #NSCLC *Hendriks, L. E., et al. (2023). Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 34(4), 339–357.

We're #hiring a new Director Strategic Accounts US North East in United States. Apply today or share this post with your network.

We're #hiring a new Director Strategic Accounts US South East in United States. Apply today or share this post with your network.

We are excited to introduce 👉 two new innovative molecular diagnostic assays 👈 that mark a significant advancement in biomarker testing in breast cancer! 1️⃣ APIS ESR1 dPCR Kit*: https://lnkd.in/eTwM9kGf - Wide target coverage: detects 11 ESR1 mutations - High sensitivity & specificity: ≤ 0.1% MAF with no WT detection - Instrument agnostic: compatible with most digital PCR systems 2️⃣ APIS PIK3CA qPCR Kit*: https://lnkd.in/eDjG6p5H - Streamlined workflow: detects > 95% of actionable PIK3CA mutations - High sensitivity: ≤ 0.5% MAF - Multiple sample types: FFPE tumor tissue or plasma 🔍 Discover our Breast Cancer Assay Portfolio: https://lnkd.in/eBPR87Hu *Distributed by Biocartis for Research Use Only (RUO), not for use in diagnostic procedures. Data and conclusions have not been validated by Biocartis NV. #Biocartis #Idylla #APIS #ESR1 #PIK3CA #AKT1 #BreastCancer APIS Assay Technologies Ltd.

Sometimes, the easiest solution can have the most life-changing impact ☃️ Molecular biomarker results in ONLY 3 HOURS! 💡THINK IDYLLA™ https://lnkd.in/gh9nKbMA ⭐ Biocartis wishes you a wonderful holiday season & a joyful 2025! ⭐ And don’t forget, the easiest solution is often right under your nose… 🥕 #Biocartis #Idylla #HappyHolidays #BiomarkerTesting #MolecularDiganostics